PF-04523655 + ranibizumab

PF-04523655 + ranibizumab is a combination therapy consisting of PF-04523655, a synthetic and chemically modified 19-nucleotide double-stranded small interfering RNA (siRNA) targeting the RTP801 gene, and ranibizumab, a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A). The combination is administered via intravitreal injection for ophthalmic indications. PF-04523655 acts by silencing RTP801 expression to reduce pathological angiogenesis and vascular leakage in retinal diseases. Ranibizumab binds to VEGF-A, inhibiting its activity and thereby reducing neovascularization and vascular permeability. This combination has been investigated primarily for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), with studies suggesting potential additive or synergistic effects on visual acuity improvement compared to monotherapy[1][2][4].